Back to top
more

Addus HomeCare (ADUS)

(Delayed Data from NSDQ)

$104.96 USD

104.96
199,146

-1.82 (-1.70%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $105.03 +0.07 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (62 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

QIAGEN (QGEN) Expands Enzyme Offering to Aid Laboratory

by Zacks Equity Research

QIAGEN is a one-stop shop for all research needs, including solutions for sample preparation, automation and bioinformatics with enzyme offering expansion.

Zacks Equity Research

National Vision (EYE) Plans to Open New Stores Amid Macro Woes

by Zacks Equity Research

National Vision (EYE) plans to continue executing core growth initiatives and further investing in competitive advantages.

Zacks Equity Research

Abbott (ABT) Expands in Electrophysiology With New FDA Nod

by Zacks Equity Research

Abbott (ABT) notes that using TactiFlex catheter can lead to reduced procedure times and better safety compared to the company's previous generation catheters.

Zacks Equity Research

Hologic (HOLX) Gets FDA Nod for Multiplexed Respiratory Test

by Zacks Equity Research

Hologic's (HOLX) Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is done using the fully-automated, high-throughput Panther Fusion system.

Zacks Equity Research

Abbott's (ABT) Assert-IQ Cardiac Monitor Receives FDA Approval

by Zacks Equity Research

Abbott's (ABT) latest approval adds to its line-up of remote patient management and treatment tools that can support doctors more effectively.

Zacks Equity Research

STERIS (STE) Continues to Face Dull Dental Sales, Margin Woes

by Zacks Equity Research

STERIS (STE) competes for pharmaceutical, research and industrial customers against several large companies that have robust product portfolios and global reach.

Zacks Equity Research

Edwards Lifesciences' (EW) TAVR Study Outcome Favorable

by Zacks Equity Research

Edwards Lifesciences' (EW) latest findings of the study confirm the value of the Edwards Benchmark programme for standardizing clinical pathways for patients undergoing TAVR in Europe.

Zacks Equity Research

Here's Why Investors Should Retain Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL) on its strong execution of strategies, disciplined cost management and revenue timing.

Zacks Equity Research

ADUS vs. USPH: Which Stock Is the Better Value Option?

by Zacks Equity Research

ADUS vs. USPH: Which Stock Is the Better Value Option?

Zacks Equity Research

Medtronic's (MDT) Global Market Share Strong, FX Headwind Stays

by Zacks Equity Research

Within cardiac rhythm management, Medtronic's (MDT) pacing business continues to outperform the market, banking on strong global growth of its Micra leadless pacemaker family.

Zacks Equity Research

LabCorp (LH) Expands Laboratory Relationship With New Pact

by Zacks Equity Research

LabCorp's (LH) recent partnership will expand healthcare access, offer advanced diagnostic tools and guarantee that both patients and doctors can afford the treatments they get.

Zacks Equity Research

HCA Healthcare (HCA) Gains 29% in a Year: More Upside Left?

by Zacks Equity Research

HCA Healthcare (HCA) is well-poised for growth on the back of higher revenues, a diversified treatment network and sound operating cash flows.

Zacks Equity Research

Here's Why You Should Hold Molina (MOH) in Your Portfolio

by Zacks Equity Research

Molina's (MOH) inorganic growth activities, financial flexibility and well-performing Medicaid and Medicare segments poise it for growth.

Zacks Equity Research

Is Addus HomeCare (ADUS) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Aparajita Dutta headshot

Bet on These 5 Low Leverage Stocks to Avoid Market Woes

by Aparajita Dutta

The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You may buy ELF, HST, ALK, ADUS & INSW

Zacks Equity Research

Here's Why Addus HomeCare (ADUS) is Poised for a Turnaround After Losing -24.6% in 4 Weeks

by Zacks Equity Research

Addus HomeCare (ADUS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

Addus HomeCare (ADUS) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Addus HomeCare (ADUS) delivered earnings and revenue surprises of 7.78% and 1.03%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ADUS vs. USPH: Which Stock Is the Better Value Option?

by Zacks Equity Research

ADUS vs. USPH: Which Stock Is the Better Value Option?

Zacks Equity Research

Option Care (OPCH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Option Care (OPCH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Quest Diagnostics (DGX) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 3.55% and 5.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?

by Zacks Equity Research

Here is how Amphastar Pharmaceuticals (AMPH) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.

Zacks Equity Research

Addus HomeCare (ADUS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Philips (PHG) Drives Healthcare Prospects With Enhanced Dataset

by Zacks Equity Research

Philips (PHG) announces its expansion with MIT IMES, which will help researchers and educators access a new critical care dataset.

Zacks Equity Research

ADUS or USPH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ADUS vs. USPH: Which Stock Is the Better Value Option?

Zacks Equity Research

Are Medical Stocks Lagging Humana (HUM) This Year?

by Zacks Equity Research

Here is how Humana (HUM) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.